Cargando…

Clinicopathologic characteristics and prognostic factors for HER2-positive patients with metastatic breast cancer in southern China

INTRODUCTION: The aim of the study was to analyze clinicopathologic characteristics and survival and to identify prognostic factors for Chinese patients with HER2-positive metastatic breast cancer. MATERIAL AND METHODS: A total of 243 patients with HER2-positive metastatic breast cancer, treated dur...

Descripción completa

Detalles Bibliográficos
Autores principales:	Qin, Tao, Yuan, Zhong-Yu, Peng, Rou-Jun, Bai, Bing, Zeng, Yin-Duo, Shi, Yan-Xia, Teng, Xiao-Yu, Liu, Dong-Geng, Wang, Shu-Sen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Termedia Publishing House 2015
Materias:	Clinical Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4495150/ https://www.ncbi.nlm.nih.gov/pubmed/26170847 http://dx.doi.org/10.5114/aoms.2015.52356

Ejemplares similares

Clinicopathological features of HER2 positive metastatic colorectal cancer and survival analysis of anti-HER2 treatment
por: Yang, Liu, et al.
Publicado: (2022)

Clinicopathological characteristics, evolution, treatment pattern and outcomes of hormone-receptor-positive/HER2-low metastatic breast cancer
por: You, Shuhui, et al.
Publicado: (2023)

Clinicopathologic characteristics of HER2-positive pure mucinous carcinoma of the breast
por: Jang, Yunjeong, et al.
Publicado: (2020)

The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
por: Pizzuti, Laura, et al.
Publicado: (2021)

Impacts of clinicopathological factors on efficacy of trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer
por: Nakajima, Hiromichi, et al.
Publicado: (2022)

Prevalence of HER2 Positivity and Its Clinicopathological Correlation in Locally Advanced/Metastatic Gastric Cancer Patients in Malaysia
por: Rajadurai, Pathmanathan, et al.
Publicado: (2017)

Clinicopathological features and Borrmann classification associated with HER2-positive in primary gastric cancer
por: Dai, Xiaomin, et al.
Publicado: (2019)

Clinicopathologic features, genomic profiles and outcomes of younger vs. older Chinese hormone receptor-positive (HR+)/HER2-negative (HER2-) metastatic breast cancer patients
por: Wang, Jinhao, et al.
Publicado: (2023)

Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma
por: Yoshikawa, D, et al.
Publicado: (2008)

HER2-positive breast cancer patients receiving trastuzumab treatment obtain prognosis comparable with that of HER2-negative breast cancer patients
por: Qin, Tao, et al.
Publicado: (2013)

Long-term survivor characteristics in HER2-positive metastatic breast cancer from registHER
por: Yardley, D A, et al.
Publicado: (2014)

Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas
por: Li, Qingguo, et al.
Publicado: (2011)

Prognostic Value of Pretreatment Neutrophil-to-Lymphocyte Ratio in HER2-Positive Metastatic Breast Cancer
por: Shao, Bin, et al.
Publicado: (2022)

Circulating tumor cells in HER2-positive metastatic breast cancer patients: a valuable prognostic and predictive biomarker
por: Liu, Yi, et al.
Publicado: (2013)

HER2 Positive and HER2 Negative Classical Type Invasive Lobular Carcinomas: Comparison of Clinicopathologic Features
por: He, Lin, et al.
Publicado: (2021)

Clinicopathological characteristics of patients with HER2-positive breast cancer and the efficacy of trastuzumab in the People’s Republic of China
por: Zhou, Ping, et al.
Publicado: (2016)

Her2-Positive and Microsatellite Instability Status in Gastric Cancer—Clinicopathological Implications
por: Bermúdez, Ana, et al.
Publicado: (2021)

The clinicopathological parameters and prognostic significance of HER2 expression in gastric cancer patients: a meta-analysis of literature
por: Lei, Yu-ying, et al.
Publicado: (2017)

Analysis of the clinicopathological characteristics and prognosis of triple-positive breast cancer and HER2-positive breast cancer—A retrospective study
por: Ma, Dongxu, et al.
Publicado: (2023)

Genomic characteristics of trastuzumab-resistant Her2-positive metastatic breast cancer
por: de Oliveira Taveira, Mateus, et al.
Publicado: (2017)

Evaluation of HER2 Positivity Based on Clinicopathological Findings in HER2 Borderline Tumors in Iranian Patients with Breast Cancer
por: Omranipour, Ramesh, et al.
Publicado: (2023)

Prognostic Value of Plasma HER2 Gene Copy Number in HER2-Positive Metastatic Breast Cancer Treated with First-Line Trastuzumab
por: Ran, Ran, et al.
Publicado: (2020)

Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis
por: Wang, Hong-Bo, et al.
Publicado: (2017)

Clinicopathological values of PD-L1 expression in HER2-positive breast cancer
por: Kurozumi, Sasagu, et al.
Publicado: (2019)

Prognostic and predictive role of spatially positioned tumour infiltrating lymphocytes in metastatic HER2 positive breast cancer treated with trastuzumab
por: Honkanen, Tiia J., et al.
Publicado: (2017)

Prognostic nomogram for female patients suffering from non-metastatic Her2 positive breast cancer: A SEER-based study
por: Wu, Jiangwen, et al.
Publicado: (2022)

Clinicopathological and prognostic significance of platelet-to-lymphocyte ratio in patients with hepatocellular carcinoma
por: Song, Wei, et al.
Publicado: (2016)

Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China
por: Xue, Cong, et al.
Publicado: (2012)

Efficacy and Safety of Anti-HER2 Targeted Therapy for Metastatic HR-Positive and HER2-Positive Breast Cancer: A Bayesian Network Meta-Analysis
por: Wu, Xian-Meng, et al.
Publicado: (2023)

Clinicopathological characteristics and prognostic factors of primary pulmonary lymphoma
por: He, Huayu, et al.
Publicado: (2021)

HER2-positive Metastatic Melanoma: A Cautionary Tale!
por: Cui, Xiaoyan, et al.
Publicado: (2020)

Trastuzumab Plus Endocrine Therapy or Chemotherapy as First-line Treatment for Patients with Hormone Receptor–Positive and HER2-Positive Metastatic Breast Cancer (SYSUCC-002)
por: Hua, Xin, et al.
Publicado: (2022)

Clinicopathological factors associated with HER2-positive gastric cancer: A meta-analysis: Erratum
Publicado: (2017)

HER2 heterogeneity is a poor prognosticator for HER2-positive gastric cancer
por: Kaito, Akio, et al.
Publicado: (2019)

HER2 and uPAR cooperativity contribute to metastatic phenotype of HER2-positive breast cancer
por: Chandran, Vineesh Indira, et al.
Publicado: (2015)

Expression of SATB1 and HER2 in breast cancer and the correlations with clinicopathologic characteristics
por: Liu, Xiangdong, et al.
Publicado: (2015)

Clinicopathological characteristics of HER2-low breast cancer: a retrospective study
por: Yang, Man, et al.
Publicado: (2023)

Comparison of clinicopathological characteristics and response to neoadjuvant chemotherapy between HER2-low and HER2-zero breast cancer
por: Zhou, Shuling, et al.
Publicado: (2022)

Clinicopathological Characteristics and Prognostic Factors of Intrahepatic Biliary Cystadenocarcinoma
por: Xu, Ming-Yue, et al.
Publicado: (2015)

The Effectiveness of Lapatinib in HER2-Positive Metastatic Breast Cancer Patients Pretreated With Multiline Anti-HER2 Treatment: A Retrospective Study in China
por: Wang, Xinzhao, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1kopvpve4crc1c00rm68msk0lc